摘要
目的观察并比较非布司他与别嘌呤醇治疗痛风伴高尿酸血症患者的疗效和安全性。方法将门诊60例痛风伴高尿酸血症的患者按随机数字表法分为3组:A组口服非布司他片40mg/d,B组口服非布司他片80mg/d,C组口服300mg/d别嘌呤醇片。比较3组患者治疗前及治疗后4、12、20周血尿酸水平、肝肾功能及不良反应发生情况。结果治疗后3组患者血尿酸水平均较治疗前下降,差异均有统计学意义(均P<0.05),且B组患者血尿酸下降幅度均较A组、C组更显著,差异有统计学意义(P<0.05),A组与C组比较,差异无统计学意义(P>0.05)。出现消化道症状A组2例(10.0%),B组3例(15.0%),C组1例(10.0%),皮肤瘙痒1例(10.0%),差异无统计学意义(P>0.05)。结论非布司他、别嘌呤醇是治疗痛风伴高尿酸血症的有效方案,其中B组口服非布司他片80mg/d疗效更佳。
Objective To compare the efficacy and safety of febuxostat with allopurinol in treatment of gout patients.Methods Sixty patients with gout were randomly divided into three groups：group A received febuxostat 40mg/d,group B received febuxostat 80mg/d and group C received allopurinol 300mg/d.The uric acid levels were measured 4,12,and 20 weeks after treatment.Results The serum uric acid levels were reduced after treatment in all three groups（P〈0.05）,while the uric acid levels in group B were lower than those in group A and group C（P〈0.05）.There was no significant difference in teh incidence of adverse events among three groups（P〉0.05）.Conclusion Febuxostat and allopurinol are effective and safe in treatment of gout with hyperuricemia,and febuxostat 80mg/d has a better efficacy.
作者
赵艳红
ZHAO Yanhong(Department of Endocrinology Fenghua People＇s Hospital, Ningbo 315500, China)
出处
《浙江医学》
CAS
2018年第10期1088-1090,共3页
Zhejiang Medical Journal
